US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gyre Therapeutics

6.72

-0.0800-1.18%

Post-market: 6.800.0800+1.19%18:04 EDT

Volume:224.82K

Turnover:1.51M

Market Cap:651.60M

PE:298.88

High:7.03

Open:6.78

Low:6.58

Close:6.80

52wk High:11.78

52wk Low:6.11

Shares:96.96M

Float Shares:20.52M

Volume Ratio:1.42

T/O Rate:1.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0225

EPS(LYR):0.0481

ROE:8.21%

ROA:4.93%

PB:6.15

PE(LYR):139.78

Loading ...

Overview Company News Filings

BRIEF-Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And Pipeline

Gyre Therapeutics agrees to acquire Cullgen in $300 million all-stock deal

Gyre Therapeutics Inc - Deal Valued at About $300 Mln

THOMSON REUTERS

Gyre Therapeutics Inc: All-Stock Transaction Valued at Approximately $300 Mln

THOMSON REUTERS

Gyre Therapeutics Inc - Ping Zhang to Remain as Executive Chairman

THOMSON REUTERS

Gyre Therapeutics Enters Into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline

THOMSON REUTERS

Gyre Therapeutics Showcases Pipeline Progress and Market Leadership in Anti-Fibrotic Therapies

GNI Group's Gyre Therapeutics Advances F351 Drug Toward Conditional Approval in China

MT Newswires Live

Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news

Sector Update: Health Care Stocks Lower Premarket Monday

MT Newswires Live

Gyre Therapeutics Gets Regulatory Priority Review for Liver Fibrosis Treatment in China

MT Newswires Live

Gyre Therapeutics Inc - Plans Nda Submission for Hydronidone in First Half of 2026

THOMSON REUTERS

Gyre Therapeutics Announces Alignment With China’s Cde on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-Nda Meeting

THOMSON REUTERS

Gyre Therapeutics Gains CDE Alignment for Hydronidone Conditional Approval NDA in China

US High Growth Tech Stocks to Watch

Simply Wall St.

Exploring High Growth Tech Stocks in the US Market

Simply Wall St.

Gyre Therapeutics Reports Strong Q3 2025 Results

Gyre Therapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview

Gyre Therapeutics Q3 EPS $0.03 Beats $(0.02) Estimate, Sales $30.600M Miss $32.930M Estimate

Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GYRE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":6.72,"timestamp":1774036800000,"preClose":6.8,"halted":0,"volume":224816,"hourTrading":{"tag":"盘后","latestPrice":6.8,"preClose":6.72,"latestTime":"18:04 EDT","volume":6457,"amount":43415.382,"timestamp":1774044241932,"change":0.08,"changeRate":0.011905,"amplitude":0.011905},"delay":0,"changeRate":-0.011764705882352951,"floatShares":20523000,"shares":96963600,"eps":0.022484,"marketStatus":"Market Closed","change":-0.08,"latestTime":"03-20 16:00:00 EDT","open":6.78,"high":7.0253,"low":6.58,"amount":1514714.1441232,"amplitude":0.065485,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.022484,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":6.8,"preHourTrading":{"tag":"盘前","latestPrice":6.95,"preClose":6.8,"latestTime":"08:00 EDT","volume":2546,"amount":17986.6584764,"timestamp":1774008021538,"change":0.15,"changeRate":0.022059,"amplitude":0.048529},"postHourTrading":{"tag":"盘后","latestPrice":6.8,"preClose":6.72,"latestTime":"18:04 EDT","volume":6457,"amount":43415.382,"timestamp":1774044241932,"change":0.08,"changeRate":0.011905,"amplitude":0.011905},"volumeRatio":1.4185651488048474,"impliedVol":1.2845,"impliedVolPercentile":0.8235},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":20523000,"roa":"4.93%","roe":"8.21%","lyrEps":0.048077,"volumeRatio":1.4185651488048474,"shares":96963600,"dividePrice":0,"high":7.0253,"amplitude":0.065485,"preClose":6.8,"low":6.58,"week52Low":6.11,"pbRate":"6.15","psRate":"5.59","week52High":11.78,"institutionHeld":0.1067,"latestPrice":6.72,"eps":0.022484,"divideRate":0,"volume":224816,"delay":0,"ttmEps":0.022484,"open":6.78,"prevYearClose":7.06,"prevWeekClose":7.555,"prevMonthClose":8.24,"prevQuarterClose":7.06,"fiveDayClose":7.555,"twentyDayClose":8.28,"sixtyDayClose":7.19},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-12","symbol":"GYRE","fiscalQuarterEnding":"2025/12","expectedEps":0.08,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":0.04},{"market":"US","date":"2025-11-07","symbol":"GYRE","fiscalQuarterEnding":"2025/09","expectedEps":0.05,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.05},{"market":"US","date":"2025-08-11","symbol":"GYRE","fiscalQuarterEnding":"2025/06","expectedEps":0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":0.02},{"market":"US","date":"2025-05-09","symbol":"GYRE","fiscalQuarterEnding":"2025/03","expectedEps":0.03,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":0},{"market":"US","date":"2025-03-17","symbol":"GYRE","fiscalQuarterEnding":"2024/12","expectedEps":0.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"post","actualEps":0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1760155200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2026-03-20","current":298.879203,"percent":0.836134,"low":-11548.718266,"twenty":-14.817461,"median":66.926893,"eighty":112.457994,"high":193.429414,"avg":-663.516276,"sd":2508.353473,"marketCap":620935247},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789},{"date":"2025-04-25","current":70.645053,"twenty":-30.585076,"median":-12.780906,"eighty":-10.377285,"marketCap":853745471},{"date":"2025-05-02","current":72.449806,"twenty":-30.310846,"median":-12.626921,"eighty":-10.338636,"marketCap":875555902},{"date":"2025-05-09","current":73.535777,"twenty":-30.136978,"median":-12.473999,"eighty":-10.164715,"marketCap":888679866},{"date":"2025-05-16","current":132.923099,"twenty":-29.947887,"median":-12.417259,"eighty":-9.938068,"marketCap":963825388},{"date":"2025-05-23","current":136.20365,"twenty":-29.754799,"median":-12.327984,"eighty":-9.652614,"marketCap":987612669},{"date":"2025-05-30","current":117.840031,"twenty":-29.349619,"median":-12.308068,"eighty":-9.440044,"marketCap":854458067},{"date":"2025-06-06","current":99.64599,"twenty":-28.753768,"median":-12.251767,"eighty":50.257139,"marketCap":722533070},{"date":"2025-06-13","current":100.896253,"twenty":-28.630129,"median":-12.168656,"eighty":56.159719,"marketCap":731598729},{"date":"2025-06-20","current":104.146938,"twenty":-27.795567,"median":-12.087508,"eighty":59.335648,"marketCap":755169444},{"date":"2025-06-27","current":92.269436,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"marketCap":669045678},{"date":"2025-07-03","current":101.646411,"twenty":-26.790554,"median":-11.75017,"eighty":66.71,"marketCap":737038125},{"date":"2025-07-11","current":97.645568,"twenty":-23.367997,"median":-11.701017,"eighty":68.524795,"marketCap":708028014},{"date":"2025-07-18","current":92.394462,"twenty":-17.913275,"median":-11.686523,"eighty":70.505622,"marketCap":669952244},{"date":"2025-07-25","current":92.269436,"twenty":-17.24169,"median":-11.594732,"eighty":71.634434,"marketCap":669045678},{"date":"2025-08-01","current":88.143567,"twenty":-16.863516,"median":-11.531927,"eighty":73.525921,"marketCap":639129001},{"date":"2025-08-08","current":90.018962,"twenty":-16.53533,"median":-11.498109,"eighty":77.782591,"marketCap":652727491},{"date":"2025-08-15","current":179.246974,"twenty":-16.326683,"median":-11.42614,"eighty":87.268382,"marketCap":746563646},{"date":"2025-08-22","current":164.643977,"twenty":-16.268001,"median":-11.353175,"eighty":89.218793,"marketCap":685742166},{"date":"2025-08-29","current":180.563196,"twenty":-16.183906,"median":-11.256552,"eighty":90.29402,"marketCap":752045713},{"date":"2025-09-05","current":165.298192,"twenty":-16.049822,"median":-11.217903,"eighty":91.769331,"marketCap":688466969},{"date":"2025-09-12","current":177.074053,"twenty":-16.011538,"median":-11.179254,"eighty":92.594504,"marketCap":737513429},{"date":"2025-09-19","current":167.696978,"twenty":-15.943032,"median":-11.12128,"eighty":93.569709,"marketCap":698457915},{"date":"2025-09-26","current":158.974119,"twenty":-15.763593,"median":-11.111618,"eighty":95.145041,"marketCap":662127204},{"date":"2025-10-03","current":163.989763,"twenty":-15.70726,"median":-11.048813,"eighty":96.920416,"marketCap":683017363},{"date":"2025-10-10","current":155.921118,"twenty":-15.633582,"median":-10.966684,"eighty":99.846032,"marketCap":649411455},{"date":"2025-10-17","current":190.594485,"twenty":-15.61523,"median":-10.876478,"eighty":100.896253,"marketCap":793826030},{"date":"2025-10-24","current":179.472839,"twenty":-15.600803,"median":-10.763776,"eighty":101.646411,"marketCap":747504374},{"date":"2025-10-31","current":166.824692,"twenty":-15.546428,"median":-10.691308,"eighty":105.447211,"marketCap":694824844},{"date":"2025-11-07","current":160.064476,"twenty":-15.429294,"median":-10.618842,"eighty":111.643728,"marketCap":666668543},{"date":"2025-11-14","current":110.418625,"twenty":-15.377823,"median":-10.570531,"eighty":112.102687,"marketCap":734394278},{"date":"2025-11-21","current":102.355879,"twenty":-15.373231,"median":-10.435259,"eighty":110.254637,"marketCap":680768953},{"date":"2025-11-28","current":105.908954,"twenty":-15.35855,"median":-10.377285,"eighty":109.598685,"marketCap":704400452},{"date":"2025-12-05","current":107.958805,"twenty":-15.300832,"median":-10.338636,"eighty":109.462028,"marketCap":718034009},{"date":"2025-12-12","current":107.548834,"twenty":-15.279098,"median":-10.299987,"eighty":109.871999,"marketCap":715307298},{"date":"2025-12-19","current":100.442685,"twenty":-15.279098,"median":-10.179208,"eighty":109.598685,"marketCap":668044300},{"date":"2025-12-26","current":98.256178,"twenty":-15.261711,"median":-10.046352,"eighty":109.489359,"marketCap":653501839},{"date":"2026-01-02","current":96.479641,"twenty":-15.250843,"median":-9.954769,"eighty":109.29804,"marketCap":641686089},{"date":"2026-01-09","current":103.449133,"twenty":-15.243518,"median":-9.652614,"eighty":109.106721,"marketCap":688040184},{"date":"2026-01-16","current":105.22567,"twenty":-15.23799,"median":-9.652614,"eighty":108.560094,"marketCap":699855933},{"date":"2026-01-23","current":110.008655,"twenty":-15.222589,"median":-9.517342,"eighty":109.134052,"marketCap":731667567},{"date":"2026-01-30","current":112.195163,"twenty":-15.163907,"median":-9.314435,"eighty":109.544022,"marketCap":746210028},{"date":"2026-02-06","current":102.629193,"twenty":-15.092184,"median":51.163441,"eighty":109.680679,"marketCap":682586761},{"date":"2026-02-13","current":106.865551,"twenty":-15.037849,"median":54.920332,"eighty":109.544022,"marketCap":710762779},{"date":"2026-02-20","current":115.064954,"twenty":-14.972646,"median":56.469566,"eighty":109.844668,"marketCap":765297008},{"date":"2026-02-27","current":116.431521,"twenty":-14.918384,"median":59.41311,"eighty":110.555282,"marketCap":774386046},{"date":"2026-03-06","current":107.002208,"twenty":-14.903389,"median":60.420111,"eighty":111.484548,"marketCap":711671683},{"date":"2026-03-13","current":141.117848,"twenty":-14.871908,"median":65.067812,"eighty":112.058506,"marketCap":709399423},{"date":"2026-03-20","current":123.520041,"twenty":-14.817461,"median":66.926893,"eighty":112.457994,"marketCap":620935247}],"updateTime":1774124040078},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616261337","title":"BRIEF-Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2616261337","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616261337?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:29","pubTimestamp":1772458179,"startTime":"0","endTime":"0","summary":"BRIEF-Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And PipelineMarch 2 (Reuters) - Gyre Therapeutics Inc GYRE.O:GYRE THERAPEUTICS ENTERS INT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA8XW1QH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2616322093","title":"Gyre Therapeutics agrees to acquire Cullgen in $300 million all-stock deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2616322093","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616322093?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:02","pubTimestamp":1772456545,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics has agreed to acquire privately held Cullgen in an all-stock deal valued at about $300 million, adding Cullgen’s targeted protein degradation and degrader-antibody conjugate platform and pipeline. Cullgen will become a wholly owned subsidiary, with Cullgen CEO Ying Luo expected to become president and CEO of Gyre, while Gyre interim CEO and executive chairman Ping Zhang will remain executive chairman. The companies expect the transaction to close early in the second quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL3qbpqx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","SG9999014005.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","GYRE","SG9999014039.USD","LU2210149790.SGD","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2616979332","title":"Gyre Therapeutics Inc - Deal Valued at About $300 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2616979332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616979332?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA8XW1QH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2616960332","title":"Gyre Therapeutics Inc: All-Stock Transaction Valued at Approximately $300 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2616960332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616960332?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA8XW1QH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2616833292","title":"Gyre Therapeutics Inc - Ping Zhang to Remain as Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2616833292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616833292?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA8XW1QH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2616333294","title":"Gyre Therapeutics Enters Into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2616333294","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616333294?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA8XW1QH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2606514755","title":"Gyre Therapeutics Showcases Pipeline Progress and Market Leadership in Anti-Fibrotic Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2606514755","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606514755?lang=en_us&edition=fundamental","pubTime":"2026-01-28 06:02","pubTimestamp":1769551375,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc. highlighted its leadership in the treatment of idiopathic pulmonary fibrosis  in China, with its product ETUARY  maintaining the largest market share for ten consecutive years. The company reported that over 150,000 IPF patients have been treated with pirfenidone across more than 3,000 hospitals and pharmacies in 870+ cities in China. Recent strategic moves include the acquisition of generic Etorel  to expand IPF treatment options, and the addition of Contiva  to establish a presence in the liver disease market, in preparation for the future launch of Hydronidone. Gyre Therapeutics also announced positive Phase 3 results for Hydronidone in chronic hepatitis B-associated liver fibrosis, with statistically significant improvements in fibrosis regression and inflammation. The safety profile showed a low rate of serious adverse events and no discontinuations due to adverse events. The company continues to advance its clinical pipeline in other chronic organ diseases,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL9X3mvL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2601556368","title":"GNI Group's Gyre Therapeutics Advances F351 Drug Toward Conditional Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2601556368","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601556368?lang=en_us&edition=fundamental","pubTime":"2026-01-06 07:48","pubTimestamp":1767656919,"startTime":"0","endTime":"0","summary":"GNI Group's  subsidiary, Gyre Therapeutics, has completed a key regulatory meeting with China's CDE following positive Phase 3 trial results for F351, according to its Tokyo bourse filing on Tuesday.The company confirmed its plan to pursue a New Drug Application via China's conditional approval pathway in the first half of 2026, with eligibility for Priority Review.Gyre will also prepare a confirmatory trial to support converting the potential conditional approval to regular approval.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2601838540","title":"Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2601838540","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601838540?lang=en_us&edition=fundamental","pubTime":"2026-01-05 23:09","pubTimestamp":1767625740,"startTime":"0","endTime":"0","summary":"U.S. stocks were higher, with the Dow Jones index gaining more than 500 points on Monday.Shares of Altimmune Inc  rose sharply during Monday's session after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH.Altimmune shares jumped 23.6% to $4.34 on Monday.Here are some other big stocks recording gains in today’s session.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/05/Section-Of-A-Financial-Newspaper-Titled-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/05/Section-Of-A-Financial-Newspaper-Titled-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49694843/altimmune-gh-research-gyre-therapeutics-and-other-big-stocks-moving-higher-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49694843/altimmune-gh-research-gyre-therapeutics-and-other-big-stocks-moving-higher-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["GH","LU1878469433.USD","BK4551","BK4599","BK4196","BK4139","GYRE","ALT","BK4585","BK4588","BK4535"],"gpt_icon":0},{"id":"2601875838","title":"Sector Update: Health Care Stocks Lower Premarket Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2601875838","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601875838?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:26","pubTimestamp":1767623174,"startTime":"0","endTime":"0","summary":"Health care stocks were lower premarket Monday, with the iShares Biotechnology ETF  slipping 0.3% and the State Street Health Care Select Sector SPDR ETF  down 0.5%.GH Research  shares were up more than 38% after the company said the US Food and Drug Administration has lifted the clinical hold on its investigational new drug application for GH001 as a potential treatment for depression, allowing the company to proceed with subject enrollment in the US.Novo Nordisk  stock was up more than 2% after the company said it will offer its 1.5 mg and 4 mg oral weight loss drug Wegovy at $149 per month to self-paying patients in the US, starting Jan. 5.Gyre Therapeutics  shares were nearly 6% higher after the company said its Chinese unit reached an agreement with China's Center for Drug Evaluation to seek conditional approval for its liver fibrosis treatment Hydronidone.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK7104","BK4539","BK4581","BK4007","IE00BZ1G4Q59.USD","BK4585","GHRS","LU0154236417.USD","GYRE","BK4599","LABU","IE00BKVL7J92.USD","BK4139","BK4532","NVO","LU1093756325.SGD","LU1093756168.USD","XBI"],"gpt_icon":1},{"id":"2601482884","title":"Gyre Therapeutics Gets Regulatory Priority Review for Liver Fibrosis Treatment in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2601482884","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601482884?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:47","pubTimestamp":1767620875,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics  said Monday its Chinese unit reached an agreement with China's Center for Drug Evaluation to seek conditional approval for its liver fibrosis treatment Hydronidone.The CDE determined that current phase 3 clinical data support the submission of an application for chronic hepatitis B-associated liver fibrosis, the company said.The company also said it intends to file the formal marketing application during H1 of 2026.It will also perform a confirmatory clinical study to track long-term health outcomes and support a transition to full regulatory approval, Gyre said.Shares of the company were up by over 2% in recent Monday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2601791885","title":"Gyre Therapeutics Inc - Plans Nda Submission for Hydronidone in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601791885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601791885?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614435,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60CC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2601752885","title":"Gyre Therapeutics Announces Alignment With China’s Cde on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-Nda Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2601752885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601752885?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614435,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2601727885","title":"Gyre Therapeutics Gains CDE Alignment for Hydronidone Conditional Approval NDA in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2601727885","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601727885?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614413,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc. announced that its majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd., has completed a Pre-New Drug Application  meeting with China's Center for Drug Evaluation  regarding its anti-fibrotic therapy, Hydronidone. The CDE agreed that Phase 3 clinical data support a conditional approval filing and priority review eligibility for Hydronidone, subject to formal approval. Gyre Pharmaceuticals plans to submit a New Drug Application  for conditional approval in the first half of 2026 and conduct a confirmatory clinical trial to support full approval in China. Hydronidone previously received Breakthrough Therapy Designation from the National Medical Products Administration .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLkxgmW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","GYRE","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","SG9999014013.SGD","BK4139","IE00B3QW5Z07.USD","BK4585","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD"],"gpt_icon":0},{"id":"2591625097","title":"US High Growth Tech Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625097","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591625097?lang=en_us&edition=fundamental","pubTime":"2025-12-16 01:09","pubTimestamp":1765818555,"startTime":"0","endTime":"0","summary":"The United States market has recently experienced declines in major stock indexes, with technology shares exerting downward pressure on the Nasdaq amid concerns about an AI bubble. In this environment, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience against broader market volatility.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/us-high-growth-tech-stocks-to-watch-8","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/us-high-growth-tech-stocks-to-watch-8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","BK4097","BK4139","GYRE","ALLT","KNSA"],"gpt_icon":0},{"id":"2583506655","title":"Exploring High Growth Tech Stocks in the US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506655","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506655?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:08","pubTimestamp":1763118488,"startTime":"0","endTime":"0","summary":"The U.S. stock market recently experienced a significant downturn, with major indices such as the Nasdaq and S&P 500 closing sharply lower, driven by a notable decline in technology shares. In this environment of heightened volatility and economic uncertainty, identifying high-growth tech stocks requires careful consideration of their potential for innovation and resilience amidst broader market fluctuations.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-20","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/exploring-high-growth-tech-stocks-in-the-us-market-20","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GYRE","BK4505","SVRA","BK4139","KNSA"],"gpt_icon":0},{"id":"2581395859","title":"Gyre Therapeutics Reports Strong Q3 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581395859","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581395859?lang=en_us&edition=fundamental","pubTime":"2025-11-08 12:19","pubTimestamp":1762575569,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc ( ($GYRE) ) has released its Q3 earnings. Here is a breakdown of the information Gyre Therapeutics Inc presented to its inves...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-strong-q3-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-strong-q3-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2581414887","title":"Gyre Therapeutics Inc  expected to post earnings of 4 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581414887","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581414887?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:38","pubTimestamp":1762533484,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc  expected to post earnings of4cents a share - Earnings Preview Gyre Therapeutics Inc GYRE.OQ GYRE.O is expected to  show a rise in quarterly revenue when it reports  results on N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ2DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2581001877","title":"Gyre Therapeutics Q3 EPS $0.03 Beats $(0.02) Estimate, Sales $30.600M Miss $32.930M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581001877","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581001877?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:07","pubTimestamp":1762513654,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.02) by 250 percent. This is a 200 percent increase over earnings of $0.01 per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48714254/gyre-therapeutics-q3-eps-0-03-beats-0-02-estimate-sales-30-600m-miss-32-930m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE"],"gpt_icon":0},{"id":"2581009971","title":"Gyre Therapeutics reports Q3 revenue of $30.6 million and net income of $5.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581009971?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:00","pubTimestamp":1762513222,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc. reported revenue of $30.6 million for the third quarter of 2025, a 20% increase year-over-year, driven by growth in ETUARY sales and contributions from Etorel and Contiva. Net income for the quarter doubled to $5.9 million, while adjusted net income rose to $8.8 million. Operating income increased by 64% to $6.9 million, and basic earnings per share improved to $0.04 from $0.01 a year earlier. For the nine months ended September 30, 2025, revenues totaled $79.4 million compared to $77.9 million for the same period in 2024. The company revised its full-year 2025 revenue guidance to $115-118 million, down from $118-128 million, due to a slower-than-expected rollout of Etorel and market uncertainty related to China's centralized procurement policy. Marketing efforts were refocused on ETUARY during the third quarter, with expectations for continued ETUARY sales growth in the fourth quarter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL7qhZlX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","GYRE","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","BK4585","IE00BKPKM429.USD","NDAQ","BK4112"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":54,"code":"91000000","status":"200"}]}}